🇺🇸 FDA
Patent

US 10023627

Vascular endothelial growth factor fusion protein

granted A61KA61K38/00A61K38/18

Quick answer

US patent 10023627 (Vascular endothelial growth factor fusion protein) held by KOREA PRIME PHARM CO., LTD. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KOREA PRIME PHARM CO., LTD.
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61K38/18, A61K39/395, A61P